Terlipressin Dosing and Dilution for Hepatorenal Syndrome
For hepatorenal syndrome with acute kidney injury (HRS-AKI), administer terlipressin 0.85 mg (equivalent to 1 mg terlipressin acetate) intravenously every 6 hours, reconstituted in 5 mL of 0.9% sodium chloride, given as a slow IV bolus over 2 minutes. 1
Preparation and Administration
Reconstitution:
- Each vial contains 0.85 mg terlipressin (1 mg terlipressin acetate)
- Add 5 mL of 0.9% sodium chloride to create a 0.85 mg/5 mL solution
- Administer through peripheral or central line (dedicated central line not required)
- Flush line after administration
- If not used immediately, store at 2°C to 8°C for up to 48 hours 1
Dosing Algorithm
Initial Dosing (Days 1-3):
- Start with 0.85 mg IV every 6 hours (total 3.4 mg/day)
- Give as slow IV bolus over 2 minutes 1
Dose Adjustment (Day 4 onwards):
- If serum creatinine decreases ≥30% from baseline: continue same dose
- If serum creatinine decreases <30% from baseline: increase to 1.7 mg IV every 6 hours (total 6.8 mg/day)
- Maximum treatment duration: 14 days 1
Alternative Continuous Infusion Regimen: The 2024 AASLD guidelines also support continuous infusion at 2 mg/24 hours IV, which can be increased every 24-48 hours up to 12 mg/day based on response 2. Research demonstrates that continuous infusion is better tolerated with fewer adverse events (35% vs 62%) and requires lower effective doses (mean 2.23 mg/day vs 3.51 mg/day) compared to bolus dosing 3.
Concomitant Albumin Administration
Albumin is mandatory with terlipressin:
Critical caveat: Recent evidence suggests albumin increases respiratory failure risk. Individualize albumin dosing based on volume status rather than fixed protocols, and consider reducing or discontinuing if volume overload develops 1.
Patient Selection Criteria
Initiate terlipressin only if:
- Stage 2 or greater HRS-AKI (serum creatinine <5 mg/dL)
- Oxygen saturation ≥90% at baseline
- NOT ACLF Grade 3
- No major cardiopulmonary or vascular disease
- No ongoing coronary, peripheral, or mesenteric ischemia 2, 1
Do NOT use if:
- Serum creatinine >5 mg/dL (unlikely to benefit)
- Hypoxia (SpO2 <90%)
- ACLF Grade 3
- Active ischemic disease 2, 1
Monitoring Requirements
Mandatory continuous monitoring:
- Pulse oximetry throughout treatment
- Discontinue immediately if SpO2 drops below 90% 1
- Monitor for volume overload (respiratory failure occurred in 14% vs 5% placebo) 1
- Assess for ischemic complications (abdominal pain, peripheral ischemia, cardiac events)
Treatment Response and Duration
Response criteria:
- Complete response: serum creatinine ≤1.5 mg/dL for ≥48 hours
- Continue treatment until creatinine returns to baseline or up to 14 days
- If no 30% decrease in creatinine after 4 days at maximum dose, consider discontinuation 4, 1
Important Clinical Pitfalls
Respiratory failure is the most serious risk - the FDA black box warning emphasizes this occurs more frequently in patients with volume overload or ACLF Grade 3. Assess volume status before each albumin dose and reduce/discontinue albumin if overload develops 1.
Bolus versus infusion: While FDA labeling describes bolus dosing 1, the 2024 AASLD guidelines recognize continuous infusion as equally valid 2, and research shows it has superior tolerability 3. The choice depends on institutional capability and patient factors.
Norepinephrine alternative: For patients with shock or those unable to tolerate terlipressin, norepinephrine (starting 0.5 mg/hour, titrated to MAP increase of ≥10 mmHg) is an acceptable alternative, though it requires ICU-level monitoring 2, 4.